We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
For the first time, patients with certain types of advanced or recurrent endometrial cancer could access a treatment shown to slow its progression
A companion report to the Lancet Oncology paper, providing trust-level analyses.
Population-based statistics on cancers treated with chemotherapy, radiotherapy and surgical tumour resection which were diagnosed between 2013 and 2016 in England.
You may need to tell DVLA if you have cancer - if you do, download the correct form to let them know
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
The first major report using world-first systemic anticancer treatment (SACT) data has been published by Lancet Oncology today (31 August 2016).
Projects granted during 2015 that have a primary purpose of basic research: oncology.
This document reviews the health effects in offspring of human populations exposed to radiotherapy and some groups exposed to chemotherapy.
EAMS scientific opinion issued to GlaxoSmithKline UK Limited for dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates...
A journal article on highly active antiretroviral therapy (HAART)
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.